FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281663681> ?p ?o ?g. }

• W4281663681 abstract "<h3>Introduction</h3> Flecainide has an established role in the treatment of common arrhythmias. The primary mechanism of action is blockade of the cardiac sodium channel, which manifests on the surface electrocardiogram (ECG) as prolongation of the PR interval and an increase in the QRS duration. The European Society of Cardiology recommends an ECG is performed within 14 days of starting therapy to screen patients for markers of proarrhythmic side effects. Our aim was to investigate the frequency of flecainide-induced arrhythmias and the role of ECG screening in contemporary practice. <h3>Methods</h3> We performed a retrospective study of all patients either initiated on flecainide or who underwent a dose uptitration our outpatient electrophysiology service over a three-year period in. Alongside basic demographic data, we collected information on risk assessment prior to prescription including baseline ECG, imaging and ischaemia testing. We also studied the effectiveness of post-initiation ECG screening, in particular whether this was performed and whether flecainide was discontinued if: QRS duration increased by >25%, there was a new high grade atrioventricular block or bundle branch block, or a type 1 Brugada pattern. Finally, we looked at the frequency of all side effects attributed to flecainide after its prescription. <h3>Results</h3> A total of 318 prescriptions were issued to 306 patients over the study period, of which 239 (75%) were new, 61 (19%) were an uptitration and 18 (6%) were a reinitiation of flecainide. The commonest indication was atrial fibrillation (241/318; 76%). The majority of patients underwent some form of risk assessment prior to prescribing flecainide, including echocardiography (316/318; 99%) and an ECG within the past six months (307/318; 97%). 47 patients (15%) had an assessment for ischaemic heart disease prior to prescription. Specific instructions on acquiring ECG screening of patients were documented in 80/318 (9%). The results of ECG screening are shown in figure 1. Side effects were reported in 32/318 (10%), however apart from syncope (6/318) and tachycardia (1/318), the majority were not cardiac in nature. <h3>Conclusion</h3> Significant QRS widening or a new bundle branch block was observed in 7% however discontinuation of flecainide occurred in a minority of cases. New high grade AV block and a Brugada pattern were rare (<1%). Whilst side effects were common, only 2% were potentially cardiac in nature and no serious harm was detected. Greater awareness of a performing a post-initiation ECG is needed and the markers for pro-arrhythmia, however most discontinuations of flecainide occurred outside this window emphasising the role for ongoing follow up and ECG monitoring. <h3>Conflict of Interest</h3> None" @default.
• W4281663681 created "2022-06-13" @default.
• W4281663681 creator A5021475773 @default.
• W4281663681 creator A5032254623 @default.
• W4281663681 creator A5037175236 @default.
• W4281663681 creator A5053730167 @default.
• W4281663681 creator A5055617875 @default.
• W4281663681 creator A5064645174 @default.
• W4281663681 creator A5065290010 @default.
• W4281663681 creator A5073590244 @default.
• W4281663681 creator A5074433373 @default.
• W4281663681 creator A5076223123 @default.
• W4281663681 date "2022-06-01" @default.
• W4281663681 modified "2023-09-28" @default.
• W4281663681 title "96 Effectiveness of outpatient screening for the proarrhythmic effects of flecainide" @default.
• W4281663681 doi "https://doi.org/10.1136/heartjnl-2022-bcs.96" @default.
• W4281663681 hasPublicationYear "2022" @default.
• W4281663681 type Work @default.
• W4281663681 citedByCount "0" @default.
• W4281663681 crossrefType "proceedings-article" @default.
• W4281663681 hasAuthorship W4281663681A5021475773 @default.
• W4281663681 hasAuthorship W4281663681A5032254623 @default.
• W4281663681 hasAuthorship W4281663681A5037175236 @default.
• W4281663681 hasAuthorship W4281663681A5053730167 @default.
• W4281663681 hasAuthorship W4281663681A5055617875 @default.
• W4281663681 hasAuthorship W4281663681A5064645174 @default.
• W4281663681 hasAuthorship W4281663681A5065290010 @default.
• W4281663681 hasAuthorship W4281663681A5073590244 @default.
• W4281663681 hasAuthorship W4281663681A5074433373 @default.
• W4281663681 hasAuthorship W4281663681A5076223123 @default.
• W4281663681 hasBestOaLocation W42816636811 @default.
• W4281663681 hasConcept C111773187 @default.
• W4281663681 hasConcept C118441451 @default.
• W4281663681 hasConcept C126322002 @default.
• W4281663681 hasConcept C164705383 @default.
• W4281663681 hasConcept C178790620 @default.
• W4281663681 hasConcept C185592680 @default.
• W4281663681 hasConcept C2426938 @default.
• W4281663681 hasConcept C2776414672 @default.
• W4281663681 hasConcept C2777008848 @default.
• W4281663681 hasConcept C2779161974 @default.
• W4281663681 hasConcept C2779837460 @default.
• W4281663681 hasConcept C2780040984 @default.
• W4281663681 hasConcept C2780350126 @default.
• W4281663681 hasConcept C42219234 @default.
• W4281663681 hasConcept C50952357 @default.
• W4281663681 hasConcept C537181965 @default.
• W4281663681 hasConcept C71924100 @default.
• W4281663681 hasConcept C98274493 @default.
• W4281663681 hasConceptScore W4281663681C111773187 @default.
• W4281663681 hasConceptScore W4281663681C118441451 @default.
• W4281663681 hasConceptScore W4281663681C126322002 @default.
• W4281663681 hasConceptScore W4281663681C164705383 @default.
• W4281663681 hasConceptScore W4281663681C178790620 @default.
• W4281663681 hasConceptScore W4281663681C185592680 @default.
• W4281663681 hasConceptScore W4281663681C2426938 @default.
• W4281663681 hasConceptScore W4281663681C2776414672 @default.
• W4281663681 hasConceptScore W4281663681C2777008848 @default.
• W4281663681 hasConceptScore W4281663681C2779161974 @default.
• W4281663681 hasConceptScore W4281663681C2779837460 @default.
• W4281663681 hasConceptScore W4281663681C2780040984 @default.
• W4281663681 hasConceptScore W4281663681C2780350126 @default.
• W4281663681 hasConceptScore W4281663681C42219234 @default.
• W4281663681 hasConceptScore W4281663681C50952357 @default.
• W4281663681 hasConceptScore W4281663681C537181965 @default.
• W4281663681 hasConceptScore W4281663681C71924100 @default.
• W4281663681 hasConceptScore W4281663681C98274493 @default.
• W4281663681 hasLocation W42816636811 @default.
• W4281663681 hasOpenAccess W4281663681 @default.
• W4281663681 hasPrimaryLocation W42816636811 @default.
• W4281663681 hasRelatedWork W1483710533 @default.
• W4281663681 hasRelatedWork W1971192386 @default.
• W4281663681 hasRelatedWork W2018638229 @default.
• W4281663681 hasRelatedWork W2071584338 @default.
• W4281663681 hasRelatedWork W2072732939 @default.
• W4281663681 hasRelatedWork W2165944273 @default.
• W4281663681 hasRelatedWork W2385890854 @default.
• W4281663681 hasRelatedWork W2413181741 @default.
• W4281663681 hasRelatedWork W4281663681 @default.
• W4281663681 hasRelatedWork W657529583 @default.
• W4281663681 isParatext "false" @default.
• W4281663681 isRetracted "false" @default.
• W4281663681 workType "article" @default.